BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 2522236)

  • 21. Control of the function of substrate-bound C4b-C3b by the complement receptor Cr1.
    Medof ME; Nussenzweig V
    J Exp Med; 1984 Jun; 159(6):1669-85. PubMed ID: 6233387
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of processing by erythrocyte C3b/C4b receptors (CR1) on binding of immune complexes to Raji cells and polymorphonuclear granulocytes.
    Rasmussen JM; Jepsen HH; Svehag SE
    Scand J Immunol; 1987 Oct; 26(4):437-44. PubMed ID: 2961050
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of hypocomplementaemia and low erythrocyte complement receptor type 1 numbers in determining abnormal immune complex clearance in humans.
    Schifferli JA; Ng YC; Paccaud JP; Walport MJ
    Clin Exp Immunol; 1989 Mar; 75(3):329-35. PubMed ID: 2522842
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complement receptor is an inhibitor of the complement cascade.
    Iida K; Nussenzweig V
    J Exp Med; 1981 May; 153(5):1138-50. PubMed ID: 6910481
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human erythrocytes inhibit complement-mediated solubilization of immune complexes.
    Dorval BL; Cosio FG; Birmingham DJ; Hebert LA
    J Immunol; 1989 Apr; 142(8):2721-7. PubMed ID: 2522967
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interaction of complement-solubilized immune complexes (IC) with CR1 receptors on human erythrocytes. Polysulfated compounds inhibit IC binding and induce IC-release from CR1.
    Jepsen HH; Ekre HP; Svehag SE
    Int J Immunopharmacol; 1987; 9(5):587-95. PubMed ID: 2442111
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interaction between immune complexes and C3b receptors on erythrocytes.
    Yoshida K; Yukiyama Y; Miyamoto T
    Clin Immunol Immunopathol; 1986 May; 39(2):213-21. PubMed ID: 2938857
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The human C3b receptor: function and role in human diseases.
    Tausk F; Gigli I
    J Invest Dermatol; 1990 Jun; 94(6 Suppl):141S-145S. PubMed ID: 2141047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concerted clearance of immune complexes bound to the human erythrocyte complement receptor: development of a heterologous mouse model.
    Henderson AL; Lindorfer MA; Kennedy AD; Foley PL; Taylor RP
    J Immunol Methods; 2002 Dec; 270(2):183-97. PubMed ID: 12379324
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Deposition of C3b and iC3b onto particulate activators of the human complement system. Quantitation with monoclonal antibodies to human C3.
    Newman SL; Mikus LK
    J Exp Med; 1985 Jun; 161(6):1414-31. PubMed ID: 2409200
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Normal function of CR1 on affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria.
    Roberts WN; Wilson JG; Wong W; Jenkins DE; Fearon DT; Austen KF; Nicholson-Weller A
    J Immunol; 1985 Jan; 134(1):512-7. PubMed ID: 2578050
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulatory proteins for the activated third and fourth components of complement (C3b and C4b) in mice. II. Identification and properties of complement receptor type 1 (CR1).
    Kinoshita T; Lavoie S; Nussenzweig V
    J Immunol; 1985 Apr; 134(4):2564-70. PubMed ID: 3156184
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Common binding region of complement factors B, H and CR1 on C3b revealed by monoclonal anti-C3d.
    Koistinen V; Wessberg S; Leikola J
    Complement Inflamm; 1989; 6(4):270-80. PubMed ID: 2527715
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune complex binding efficiency of erythrocyte complement receptor 1 (CR1).
    Madi N; Paccaud JP; Steiger G; Schifferli JA
    Clin Exp Immunol; 1991 Apr; 84(1):9-15. PubMed ID: 1826650
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Erythrocyte enhancement of C3b-mediated phagocytosis by human neutrophils in vitro: a combined effect of the erythrocyte complement receptors CR1 and erythrocyte scavengers to reactive oxygen metabolites (ROM).
    Forslid J; Hed J; Stendahl O
    Immunology; 1985 May; 55(1):97-103. PubMed ID: 3158597
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor.
    Fischer E; Kazatchkine MD; Mecarelli-Halbwachs L
    Eur J Immunol; 1984 Dec; 14(12):1111-4. PubMed ID: 6240408
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Functional characterization of non-human primate erythrocyte immune adherence receptors: implications for the uptake of immune complexes by the cells of the mononuclear phagocytic system.
    Edberg JC; Kimberly RP; Taylor RP
    Eur J Immunol; 1992 Jun; 22(6):1333-9. PubMed ID: 1376254
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heteropolymer-mediated clearance of immune complexes via erythrocyte CR1: mechanisms and applications.
    Lindorfer MA; Hahn CS; Foley PL; Taylor RP
    Immunol Rev; 2001 Oct; 183():10-24. PubMed ID: 11782244
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A soluble recombinant multimeric anti-Rh(D) single-chain Fv/CR1 molecule restores the immune complex binding ability of CR1-deficient erythrocytes.
    Oudin S; Libyh MT; Goossens D; Dervillez X; Philbert F; Réveil B; Bougy F; Tabary T; Rouger P; Klatzmann D; Cohen JH
    J Immunol; 2000 Feb; 164(3):1505-13. PubMed ID: 10640768
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Another function of erythrocytes: transport of circulating immune complexes.
    Pascual M; Schifferli JA
    Infusionsther Transfusionsmed; 1995 Oct; 22(5):310-5. PubMed ID: 8924746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.